We are analyzing https://link.springer.com/article/10.1007/s40265-018-1043-y.

Title:
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019 | Drugs
Description:
The inability to use powerful antituberculosis drugs in an increasing number of patients seems to be the biggest threat towards global tuberculosis (TB) elimination. Simplified, shorter and preferably less toxic drug regimens are being investigated for pulmonary TB to counteract emergence of drug resistance. Intensified regimens with high-dose anti-TB drugs during the first weeks of treatment are being investigated for TB meningitis to increase the survival rate among these patients. Moxifloxacin, gatifloxacin and levofloxacin are seen as core agents in case of resistance or intolerance against first-line anti-TB drugs. However, based on their pharmacokinetics (PK) and pharmacodynamics (PD), these drugs are also promising for TB meningitis and might perhaps have the potential to shorten pulmonary TB treatment if dosing could be optimized. We prepared a comprehensive summary of clinical trials investigating the outcome of TB regimens based on moxifloxacin, gatifloxacin and levofloxacin in recent years. In the majority of clinical trials, treatment success was not in favour of these drugs compared to standard regimens. By discussing these results, we propose that incorporation of extended PK/PD analysis into the armamentarium of drug-development tools is needed to clarify the role of moxifloxacin, gatifloxacin and levofloxacin for TB, using the right dose. In addition, to prevent failure of treatment or emergence of drug-resistance, PK and PD variability advocates for concentration-guided dosing in patients at risk for too low a drug-exposure.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

moxifloxacin, treatment, tuberculosis, article, google, scholar, patients, levofloxacin, drug, clinical, regimen, regimens, rifampicin, gatifloxacin, van, cas, drugs, pulmonary, study, tbm, trials, standard, trial, fluoroquinolones, resistance, compared, meningitis, dose, agents, dis, highdose, survival, outcome, sterilizing, dstb, health, analysis, data, based, drugresistant, month, phase, groningen, antitb, results, table, respir, infect, fluoroquinolone, months,

Topics {✒️}

rr/mdr-tb patient data core rr/mdr-tb agents thrice-weekly ds-tb regimen high-dose anti-tb drugs suppress drug-resistant mutants internal medicine/infectious diseases intensified antituberculosis therapy totally drug-resistant strains pre-clinical animal models disease-related intestinal dysfunction article download pdf totally drug-resistant tuberculosis world health organization powerful anti-tb agents extended pk/pd analysis core anti-tb drugs line anti-tb agents combination therapy pre-clinical study designs line anti-tb drugs mdr/rr-tb regimen mdr/rr-tb regimen [47] additional pk/pd analysis drug-resistant tb prevention hollow-fiber infection model sixth month post-treatment shorten ds-tb treatment tuberculous meningitis—authors’ reply vitro pk/pd modelling rr/mdr-tb regimens rr/mdr-tb patients [8] mdr/rr-tb patients pulmonary multidrug-resistant tuberculosis adequate early-phase treatment standard ds-tb regimen multidrug-resistant tuberculosis treatment individual patient data privacy choices/manage cookies standard ds-tb treatment thrice-weekly 4-month moxifloxacin �randomized controlled trial” mdr-tb treatment success included high-dose fluoroquinolone conventional mdr-tb regimens group analysis showed standard drug combination van der werf pubmed search mdr/rr-tb lean body mass

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019
         description:The inability to use powerful antituberculosis drugs in an increasing number of patients seems to be the biggest threat towards global tuberculosis (TB) elimination. Simplified, shorter and preferably less toxic drug regimens are being investigated for pulmonary TB to counteract emergence of drug resistance. Intensified regimens with high-dose anti-TB drugs during the first weeks of treatment are being investigated for TB meningitis to increase the survival rate among these patients. Moxifloxacin, gatifloxacin and levofloxacin are seen as core agents in case of resistance or intolerance against first-line anti-TB drugs. However, based on their pharmacokinetics (PK) and pharmacodynamics (PD), these drugs are also promising for TB meningitis and might perhaps have the potential to shorten pulmonary TB treatment if dosing could be optimized. We prepared a comprehensive summary of clinical trials investigating the outcome of TB regimens based on moxifloxacin, gatifloxacin and levofloxacin in recent years. In the majority of clinical trials, treatment success was not in favour of these drugs compared to standard regimens. By discussing these results, we propose that incorporation of extended PK/PD analysis into the armamentarium of drug-development tools is needed to clarify the role of moxifloxacin, gatifloxacin and levofloxacin for TB, using the right dose. In addition, to prevent failure of treatment or emergence of drug-resistance, PK and PD variability advocates for concentration-guided dosing in patients at risk for too low a drug-exposure.
         datePublished:2019-01-07T00:00:00Z
         dateModified:2019-01-07T00:00:00Z
         pageStart:161
         pageEnd:171
         sameAs:https://doi.org/10.1007/s40265-018-1043-y
         keywords:
            Pharmacotherapy
            Pharmacology/Toxicology
            Internal Medicine
         image:
         isPartOf:
            name:Drugs
            issn:
               1179-1950
               0012-6667
            volumeNumber:79
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:A. D. Pranger
               url:http://orcid.org/0000-0001-5920-0734
               affiliation:
                     name:University of Groningen, University Medical Center Groningen
                     address:
                        name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                        type:PostalAddress
                     type:Organization
                     name:Leiden University Medical Center
                     address:
                        name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:T. S. van der Werf
               affiliation:
                     name:University of Groningen, University Medical Center Groningen
                     address:
                        name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                        type:PostalAddress
                     type:Organization
                     name:University of Groningen, University Medical Center Groningen
                     address:
                        name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. G. W. Kosterink
               affiliation:
                     name:University of Groningen, University Medical Center Groningen
                     address:
                        name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                        type:PostalAddress
                     type:Organization
                     name:University of Groningen
                     address:
                        name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. W. C. Alffenaar
               affiliation:
                     name:University of Groningen, University Medical Center Groningen
                     address:
                        name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019
      description:The inability to use powerful antituberculosis drugs in an increasing number of patients seems to be the biggest threat towards global tuberculosis (TB) elimination. Simplified, shorter and preferably less toxic drug regimens are being investigated for pulmonary TB to counteract emergence of drug resistance. Intensified regimens with high-dose anti-TB drugs during the first weeks of treatment are being investigated for TB meningitis to increase the survival rate among these patients. Moxifloxacin, gatifloxacin and levofloxacin are seen as core agents in case of resistance or intolerance against first-line anti-TB drugs. However, based on their pharmacokinetics (PK) and pharmacodynamics (PD), these drugs are also promising for TB meningitis and might perhaps have the potential to shorten pulmonary TB treatment if dosing could be optimized. We prepared a comprehensive summary of clinical trials investigating the outcome of TB regimens based on moxifloxacin, gatifloxacin and levofloxacin in recent years. In the majority of clinical trials, treatment success was not in favour of these drugs compared to standard regimens. By discussing these results, we propose that incorporation of extended PK/PD analysis into the armamentarium of drug-development tools is needed to clarify the role of moxifloxacin, gatifloxacin and levofloxacin for TB, using the right dose. In addition, to prevent failure of treatment or emergence of drug-resistance, PK and PD variability advocates for concentration-guided dosing in patients at risk for too low a drug-exposure.
      datePublished:2019-01-07T00:00:00Z
      dateModified:2019-01-07T00:00:00Z
      pageStart:161
      pageEnd:171
      sameAs:https://doi.org/10.1007/s40265-018-1043-y
      keywords:
         Pharmacotherapy
         Pharmacology/Toxicology
         Internal Medicine
      image:
      isPartOf:
         name:Drugs
         issn:
            1179-1950
            0012-6667
         volumeNumber:79
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:A. D. Pranger
            url:http://orcid.org/0000-0001-5920-0734
            affiliation:
                  name:University of Groningen, University Medical Center Groningen
                  address:
                     name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                     type:PostalAddress
                  type:Organization
                  name:Leiden University Medical Center
                  address:
                     name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:T. S. van der Werf
            affiliation:
                  name:University of Groningen, University Medical Center Groningen
                  address:
                     name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                     type:PostalAddress
                  type:Organization
                  name:University of Groningen, University Medical Center Groningen
                  address:
                     name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. G. W. Kosterink
            affiliation:
                  name:University of Groningen, University Medical Center Groningen
                  address:
                     name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                     type:PostalAddress
                  type:Organization
                  name:University of Groningen
                  address:
                     name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. W. C. Alffenaar
            affiliation:
                  name:University of Groningen, University Medical Center Groningen
                  address:
                     name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Drugs
      issn:
         1179-1950
         0012-6667
      volumeNumber:79
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Groningen, University Medical Center Groningen
      address:
         name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
         type:PostalAddress
      name:Leiden University Medical Center
      address:
         name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
         type:PostalAddress
      name:University of Groningen, University Medical Center Groningen
      address:
         name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
         type:PostalAddress
      name:University of Groningen, University Medical Center Groningen
      address:
         name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
         type:PostalAddress
      name:University of Groningen, University Medical Center Groningen
      address:
         name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
         type:PostalAddress
      name:University of Groningen
      address:
         name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
         type:PostalAddress
      name:University of Groningen, University Medical Center Groningen
      address:
         name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:A. D. Pranger
      url:http://orcid.org/0000-0001-5920-0734
      affiliation:
            name:University of Groningen, University Medical Center Groningen
            address:
               name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
               type:PostalAddress
            type:Organization
            name:Leiden University Medical Center
            address:
               name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:T. S. van der Werf
      affiliation:
            name:University of Groningen, University Medical Center Groningen
            address:
               name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
               type:PostalAddress
            type:Organization
            name:University of Groningen, University Medical Center Groningen
            address:
               name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
               type:PostalAddress
            type:Organization
      name:J. G. W. Kosterink
      affiliation:
            name:University of Groningen, University Medical Center Groningen
            address:
               name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
               type:PostalAddress
            type:Organization
            name:University of Groningen
            address:
               name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
               type:PostalAddress
            type:Organization
      name:J. W. C. Alffenaar
      affiliation:
            name:University of Groningen, University Medical Center Groningen
            address:
               name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
      name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
      name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
      name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
      name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
      name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
      name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

External Links {🔗}(141)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.16s.

LINK . SPRINGER . COM {}